Esperion Update On Lead Cholestrol Drug Spooks Investors
This article was originally published in Scrip
Worries Esperion Therapeutics is falling behind competitors in the race to bring the next generation of powerful cholesterol-lowering drug to market suddenly surfaced this week, sending the US biotech's share price plummeting more than 40% on Tuesday.
You may also be interested in...
Esperion Therapeutics and the FDA have failed to reach agreement on a definitive approval path for the company's cholesterol drug ETC-1002, raising the possibility of a long and more expensive development pathway for the oral therapy.
COMPASS is testing a synthetic form of psilocybin, the active “magic mushroom” ingredient, in long-term depression patients, and thinks the capsule can be approved by 2025, its co-founder tells Scrip.
Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.